Literature DB >> 2443283

Increased activity of oligo-2',5'-adenylate synthetase in Down's syndrome and epilepsy.

N Fujii1, K Oguma, M Fujii, R Fukatsu, N Takahata, M Kitabatake.   

Abstract

The level of oligo-2',5'-adenylate synthetase activity is a good marker for the response of cells to interferon. This enzyme can polymerize ATP to form oligonucleotides in the presence of double-stranded RNA, i.e. polyinosinate-cytidylate in vitro. The activity of this enzyme in peripheral blood mononuclear leucocytes was significantly increased in Down's syndrome (P less than 0.01) and epilepsy (P less than 0.01) compared with that in healthy controls, but the increase of activity was not significant in multi-infarct dementia (MID) (P greater than 0.05). Although the patients with Down's syndrome showed higher levels of this enzyme activity than the controls, interferon activity was never detected in the circulation. In addition, the serum of patients with Down's syndrome lacked the capacity to induce this enzyme in NC-37 and FL cells, and furthermore it was shown that the inhibitor of interferon activity was not found in the serum of patients. This discrepancy in Down's syndrome may be the result of the hypersensitivity of cells to interferon. On the contrary, interferon activity (32 IU/ml) was detectable in the circulation of one patient with epilepsy, and the serum of this patient had the capacity to induce this enzyme in NC-37 and FL cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2443283      PMCID: PMC1542702     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  41 in total

1.  Mortality and life-table in Down's syndrome.

Authors:  J Oster; M Mikkelsen; A Nielsen
Journal:  Acta Paediatr Scand       Date:  1975-03

2.  Lymphoblastogenesis in Down's syndrome and its inhibition by human interferon.

Authors:  D Gurari-Rotman; M Revel; B Tartakovsky; S Segal; T Hahn; Z Handzel; S Levin
Journal:  FEBS Lett       Date:  1978-10-15       Impact factor: 4.124

3.  Chromosome 21 and the cell growth inhibitory effect of human interferon preparations.

Authors:  Y H Tan
Journal:  Nature       Date:  1976-03-11       Impact factor: 49.962

4.  Interferon induction by vesicular stomatitis virus and its role in virus replication.

Authors:  J Vilcek; S Yamazaki; E A Havell
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

5.  Derangements of immunoglobulin levels, phytohemagglutinin responsiveness and T and B cell markers in Down's syndrome at different ages.

Authors:  G R Burgio; A G Ugazio; L Nespoli; A F Marcioni; A M Bottelli; F Pasquali
Journal:  Eur J Immunol       Date:  1975-09       Impact factor: 5.532

6.  The probable role of interferon in allergy.

Authors:  S V Skurkovich; E I Eremkina
Journal:  Ann Allergy       Date:  1975-12

7.  Human chromosome 21 dosage: effect on the expression of the interferon induced antiviral state.

Authors:  Y H Tan; E L Schneider; J Tischfield; C J Epstein; F H Ruddle
Journal:  Science       Date:  1974-10-04       Impact factor: 47.728

8.  Immunodeficiency in Down's syndrome: T-lymphocyte subset imbalance in trisomic children.

Authors:  G R Burgio; A Lanzavecchia; R Maccario; A Vitiello; A Plebani; A G Ugazio
Journal:  Clin Exp Immunol       Date:  1978-08       Impact factor: 4.330

9.  Immunological studies of Aging. III. Cytokinetic basis for the impaired response of lymphocytes from aged humans to plant lectins.

Authors:  B Inkeles; J B Innes; M M Kuntz; A S Kadish; M E Weksler
Journal:  J Exp Med       Date:  1977-05-01       Impact factor: 14.307

10.  The linkage of genes for the human interferon-induced antiviral protein and indophenol oxidase-B traits to chromosome G-21.

Authors:  Y H Tan; J Tischfield; F H Ruddle
Journal:  J Exp Med       Date:  1973-02-01       Impact factor: 14.307

View more
  1 in total

1.  Increased IFN-alpha-induced sensitivity but reduced reactivity of 2',5'-oligoadenylate synthetase (2,5AS) in trisomy 21 blood lymphocytes.

Authors:  A M Gerdes; M Hørder; V Bonnevie-Nielsen
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.